185 related articles for article (PubMed ID: 15353330)
1. Current vaccine adjuvants: an overview of a diverse class.
Kensil CR; Mo AX; Truneh A
Front Biosci; 2004 Sep; 9():2972-88. PubMed ID: 15353330
[TBL] [Abstract][Full Text] [Related]
2. Advances in vaccine adjuvants.
Singh M; O'Hagan D
Nat Biotechnol; 1999 Nov; 17(11):1075-81. PubMed ID: 10545912
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
Nicholls EF; Madera L; Hancock RE
Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
[TBL] [Abstract][Full Text] [Related]
4. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
5. The golden era of vaccine adjuvants.
Cabrera O; Cuello M; Lastre M; Romeu B; Balboa J; Zayas C; Pérez O
Expert Rev Vaccines; 2011 Jul; 10(7):1007-9. PubMed ID: 21806395
[TBL] [Abstract][Full Text] [Related]
6. Adjuvants for vaccines, a quest.
Audibert F
Int Immunopharmacol; 2003 Aug; 3(8):1187-93. PubMed ID: 12860174
[TBL] [Abstract][Full Text] [Related]
7. Improving vaccines by incorporating immunological coadjuvants.
Fraser CK; Diener KR; Brown MP; Hayball JD
Expert Rev Vaccines; 2007 Aug; 6(4):559-78. PubMed ID: 17669010
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections.
Eo SK; Pack C; Kumaraguru U; Rouse BT
Expert Opin Biol Ther; 2001 Mar; 1(2):213-25. PubMed ID: 11727531
[TBL] [Abstract][Full Text] [Related]
9. Synthetic vaccines: the role of adjuvants in immune targeting.
Jiang ZH; Koganty RR
Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
[TBL] [Abstract][Full Text] [Related]
10. Vaccines and vaccine adjuvants as biological response modifiers.
Speil C; Rzepka R
Infect Dis Clin North Am; 2011 Dec; 25(4):755-72. PubMed ID: 22054754
[TBL] [Abstract][Full Text] [Related]
11. Vaccine adjuvants: current challenges and future approaches.
Wilson-Welder JH; Torres MP; Kipper MJ; Mallapragada SK; Wannemuehler MJ; Narasimhan B
J Pharm Sci; 2009 Apr; 98(4):1278-316. PubMed ID: 18704954
[TBL] [Abstract][Full Text] [Related]
12. Immune effects and mechanisms of action of CpG motifs.
Krieg AM
Vaccine; 2000 Nov; 19(6):618-22. PubMed ID: 11090712
[TBL] [Abstract][Full Text] [Related]
13. Enhancing vaccines with immune stimulatory CpG DNA.
Krieg AM; Davis HL
Curr Opin Mol Ther; 2001 Feb; 3(1):15-24. PubMed ID: 11249727
[TBL] [Abstract][Full Text] [Related]
14. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
15. Heat shock proteins as vaccine adjuvants in infections and cancer.
Segal BH; Wang XY; Dennis CG; Youn R; Repasky EA; Manjili MH; Subjeck JR
Drug Discov Today; 2006 Jun; 11(11-12):534-40. PubMed ID: 16713905
[TBL] [Abstract][Full Text] [Related]
16. Modes of Action for Mucosal Vaccine Adjuvants.
Aoshi T
Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
[TBL] [Abstract][Full Text] [Related]
17. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
[TBL] [Abstract][Full Text] [Related]
18. Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds.
Banerjee J; Dey S; Ali KM; Giri B; Dash SK
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1721-1743. PubMed ID: 33632112
[TBL] [Abstract][Full Text] [Related]
19. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
Chauhan N; Tiwari S; Iype T; Jain U
Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
